Browse News

Found 11,976 articles

• Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

  5/19/2022

  Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107.

• Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

  5/19/2022

  Chinook Therapeutics, Inc. announced three mini-oral presentations on the BION-1301 and atrasentan clinical programs at the 59th ERA Congress 2022 being held virtually and live in Paris, France.

• Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

  5/19/2022

  Be Biopharma, Inc. and National Resilience, Inc. announced a strategic collaboration to advance initial programs in Be Bio’s rare disease pipeline.

• Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine

  5/18/2022

  Ascentage Pharma (6855.HK), today announced that a new preclinical study, conducted by the researchers from Fred Hutchinson Cancer Research Center, Seattle, suggests the therapeutic potential of olverembatinib (HQP1351) in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron-mediated cytokine release.

• NanoString to Webcast Presentation from the UBS 2022 Global Healthcare Conference

  5/18/2022

  NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that company management is scheduled to webcast a presentation from the 2022 UBS Global Healthcare Conference.

• Mozart Therapeutics to Present on Novel CD8 T Cell Network at the 2022 Digestive Disease Week® (DDW) Conference

  5/18/2022

  Mozart Therapeutics , a leading developer of CD8 Treg modulators in autoimmune and inflammatory disease, today announced it will present at Digestive Disease Week ®  (DDW) taking place May 21-24, 2022 in San Diego, CA and virtually.

• Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022

  5/18/2022

  Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today its participation at Preclinical Immuno-oncology Online 2022.

• Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  5/17/2022

  Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.

• Endevica Bio Appoints Prominent Cachexia Physician, Daniel Marks MD, PhD, as Chief Medical Officer

  5/16/2022

  Endevica Bio , a company developing first-in-class peptide drug candidates with better safety and efficacy properties, appointed Daniel Marks, M.D. Ph.D. as Chief Medical Officer (CMO).

• Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)

  5/16/2022

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin’s NL-201 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® .

• Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

  5/16/2022

  Seagen Inc. announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors.

• Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/16/2022

  Icosavax, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Eliem Therapeutics Reports First Quarter 2022 Financial and Business Highlights

  5/16/2022

  Eliem Therapeutics, Inc. provided a business update and reported financial results for the quarter ended March 31, 2022.

• Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting

  5/16/2022

  Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of preclinical data on two small molecule positive modulators of the HGF/MET signaling pathway, ATH-1018 and ATH-1019, at the 2022 Peripheral Nerve Society (PNS) Annual Meeting.

• Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

  5/16/2022

  Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

  5/15/2022

  Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., announced new analyses from the Phase 3 EMPOWUR Extension Study of GEMTESA, presented Sunday at the 2022 annual meeting of the American Urological Association.

• Urologists Share Latest Developments in Prostate Cancer Research

  5/15/2022

  Researchers will be presenting these prostate cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association.

• 

  Study: Inflammatory Proteins From COVID-19 May Cause Long COIVD

  5/13/2022

  New research from the Allen Institute for Immunology in Seattle has identified inflammatory proteins as a potential driver of the long COVID.

• Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

  5/13/2022

  BAILI-BIOPHARMACEUTICAL CO., LTD. ("Baili") and its wholly owned subsidiary, SystImmune, Inc ("SystImmune"), announced today that it has entered into a clinical trial collaboration and supply agreement with AstraZeneca.

• ProMIS Neurosciences Announces First Quarter 2022 Results

  5/13/2022

  ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2021.